Viviane Kunisawa Image

Viviane Kunisawa

Partner

Daniel Law

Viviane Kunisawa is a partner with Daniel Law. She is highly proficient in the field of Regulatory Law for Life Sciences, including Agribusiness, and in matters related to access to genetic resources. With substantial experience in strategic litigation, consulting, and advocacy initiatives, Viviane holds extensive expertise in patent enforcement projects and combating unfair competition, leveraging her knowledge in regulatory law to advocate for clients’ interests. With a Ph.D. title from the Ludwig-Maximilians-Universität in Munich, she conducted research on the implementation of the TRIPs Agreement in Brazil for the pharmaceutical industry as a fellow of the Max Planck Institute for Innovation and Competition, also having served as a visiting researcher at the Institute of Intellectual Property (Chizaiken) in Tokyo.

Recent Articles by Viviane Kunisawa

What’s Next After Brazil’s Enactment of the Nagoya Protocol

In a significant milestone for the preservation of biodiversity, Decree 11,865/2023, published in the Official Gazette on 12/28/2023, enacted the Nagoya Protocol in Brazil. The protocol, providing for access to genetic resources and the fair sharing of benefits arising from their use, is part of the renowned Convention on Biological Diversity (CBD). The Nagoya Protocol, in force since October 12, 2014, relates to the international commitment of 140 countries, including Brazil, to implement the objective of the CBD on the fair and equitable sharing of benefits from the use of genetic resources and the traditional knowledge associated with them (TK).

The New Legal Framework for Chemical Pesticides in Brazil

At the end of 2023, Law 14,785/2023 was published in Brazil’s official gazette, creating a new regulatory framework for chemical pesticides and environmental control products. The result of decades of discussions in the National Congress, the new law brings provisions that represent improvements to the system, such as the mandatory use of risk analysis in the process of granting registration of products and the requirement to harmonize with internationally established standards.